Endothelin in patients with chronic renal failure

Yoshihiko Saito, Nakao Kazuwa, Gotaro Shirakami, Masashi Mukoyama, Hiroshi Arai, Kiminori Hosoda, Shin ichi Suga, Yoshihiro Ogawa, Hiroo Imura

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

To investigate the pathophysiological significance of endothelin-1 (ET-1) in renal failure, we measured plasma and urine concentrations of ET-1-Like immunoreactivity (LI) by radioimmunoassay (RIA). The plasma ET-1-LI level was significantly increased in hemodialyzed and nonhemodialyzed patients with chronic renal failure (CRF). The increase in the plasma ET-1-LI level in CRF was much larger than that in other diseases in which the plasma ET-1-LI level was reported to be increased. The urine ET-1-LI level was lower, and daily excreted amounts of ET-1-LI were smaller in CRF patients than in normal subjects. These findings indicate that the increased plasma level of ET-1-LI in CRF results from the decreased clearance rate of ET-1-LI in the kidney. Gel permeation chromatographic analysis revealed that ET-1-LI in plasma from CRF consisted of small and large molecular forms of ET-1-LI. The small molecular form is presumably ET-1, and large molecular forms are big ET-1 and another component with the molecular weight of 6,000 as is the case of that in normal plasma (1). However, the ratio of the smaller to large molecular forms of ET-1-LI in CRF was 1:13 and was quite different from that in normal plasma (1:4). These observations clearly indicate that the elevation of plasma ET-1-LI level in CRF was mainly due to the increase in the large molecular form of ET-1-LI.

Original languageEnglish
Pages (from-to)S437-S439
JournalJournal of Cardiovascular Pharmacology
Volume17
Publication statusPublished - Jan 1 1991
Externally publishedYes

Fingerprint

Endothelins
Endothelin-1
Chronic Kidney Failure
Urine
Radioimmunoassay

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Saito, Y., Kazuwa, N., Shirakami, G., Mukoyama, M., Arai, H., Hosoda, K., ... Imura, H. (1991). Endothelin in patients with chronic renal failure. Journal of Cardiovascular Pharmacology, 17, S437-S439.

Endothelin in patients with chronic renal failure. / Saito, Yoshihiko; Kazuwa, Nakao; Shirakami, Gotaro; Mukoyama, Masashi; Arai, Hiroshi; Hosoda, Kiminori; Suga, Shin ichi; Ogawa, Yoshihiro; Imura, Hiroo.

In: Journal of Cardiovascular Pharmacology, Vol. 17, 01.01.1991, p. S437-S439.

Research output: Contribution to journalArticle

Saito, Y, Kazuwa, N, Shirakami, G, Mukoyama, M, Arai, H, Hosoda, K, Suga, SI, Ogawa, Y & Imura, H 1991, 'Endothelin in patients with chronic renal failure', Journal of Cardiovascular Pharmacology, vol. 17, pp. S437-S439.
Saito Y, Kazuwa N, Shirakami G, Mukoyama M, Arai H, Hosoda K et al. Endothelin in patients with chronic renal failure. Journal of Cardiovascular Pharmacology. 1991 Jan 1;17:S437-S439.
Saito, Yoshihiko ; Kazuwa, Nakao ; Shirakami, Gotaro ; Mukoyama, Masashi ; Arai, Hiroshi ; Hosoda, Kiminori ; Suga, Shin ichi ; Ogawa, Yoshihiro ; Imura, Hiroo. / Endothelin in patients with chronic renal failure. In: Journal of Cardiovascular Pharmacology. 1991 ; Vol. 17. pp. S437-S439.
@article{51f12c107f0448e08a964ff6b8b65016,
title = "Endothelin in patients with chronic renal failure",
abstract = "To investigate the pathophysiological significance of endothelin-1 (ET-1) in renal failure, we measured plasma and urine concentrations of ET-1-Like immunoreactivity (LI) by radioimmunoassay (RIA). The plasma ET-1-LI level was significantly increased in hemodialyzed and nonhemodialyzed patients with chronic renal failure (CRF). The increase in the plasma ET-1-LI level in CRF was much larger than that in other diseases in which the plasma ET-1-LI level was reported to be increased. The urine ET-1-LI level was lower, and daily excreted amounts of ET-1-LI were smaller in CRF patients than in normal subjects. These findings indicate that the increased plasma level of ET-1-LI in CRF results from the decreased clearance rate of ET-1-LI in the kidney. Gel permeation chromatographic analysis revealed that ET-1-LI in plasma from CRF consisted of small and large molecular forms of ET-1-LI. The small molecular form is presumably ET-1, and large molecular forms are big ET-1 and another component with the molecular weight of 6,000 as is the case of that in normal plasma (1). However, the ratio of the smaller to large molecular forms of ET-1-LI in CRF was 1:13 and was quite different from that in normal plasma (1:4). These observations clearly indicate that the elevation of plasma ET-1-LI level in CRF was mainly due to the increase in the large molecular form of ET-1-LI.",
author = "Yoshihiko Saito and Nakao Kazuwa and Gotaro Shirakami and Masashi Mukoyama and Hiroshi Arai and Kiminori Hosoda and Suga, {Shin ichi} and Yoshihiro Ogawa and Hiroo Imura",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "S437--S439",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Endothelin in patients with chronic renal failure

AU - Saito, Yoshihiko

AU - Kazuwa, Nakao

AU - Shirakami, Gotaro

AU - Mukoyama, Masashi

AU - Arai, Hiroshi

AU - Hosoda, Kiminori

AU - Suga, Shin ichi

AU - Ogawa, Yoshihiro

AU - Imura, Hiroo

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To investigate the pathophysiological significance of endothelin-1 (ET-1) in renal failure, we measured plasma and urine concentrations of ET-1-Like immunoreactivity (LI) by radioimmunoassay (RIA). The plasma ET-1-LI level was significantly increased in hemodialyzed and nonhemodialyzed patients with chronic renal failure (CRF). The increase in the plasma ET-1-LI level in CRF was much larger than that in other diseases in which the plasma ET-1-LI level was reported to be increased. The urine ET-1-LI level was lower, and daily excreted amounts of ET-1-LI were smaller in CRF patients than in normal subjects. These findings indicate that the increased plasma level of ET-1-LI in CRF results from the decreased clearance rate of ET-1-LI in the kidney. Gel permeation chromatographic analysis revealed that ET-1-LI in plasma from CRF consisted of small and large molecular forms of ET-1-LI. The small molecular form is presumably ET-1, and large molecular forms are big ET-1 and another component with the molecular weight of 6,000 as is the case of that in normal plasma (1). However, the ratio of the smaller to large molecular forms of ET-1-LI in CRF was 1:13 and was quite different from that in normal plasma (1:4). These observations clearly indicate that the elevation of plasma ET-1-LI level in CRF was mainly due to the increase in the large molecular form of ET-1-LI.

AB - To investigate the pathophysiological significance of endothelin-1 (ET-1) in renal failure, we measured plasma and urine concentrations of ET-1-Like immunoreactivity (LI) by radioimmunoassay (RIA). The plasma ET-1-LI level was significantly increased in hemodialyzed and nonhemodialyzed patients with chronic renal failure (CRF). The increase in the plasma ET-1-LI level in CRF was much larger than that in other diseases in which the plasma ET-1-LI level was reported to be increased. The urine ET-1-LI level was lower, and daily excreted amounts of ET-1-LI were smaller in CRF patients than in normal subjects. These findings indicate that the increased plasma level of ET-1-LI in CRF results from the decreased clearance rate of ET-1-LI in the kidney. Gel permeation chromatographic analysis revealed that ET-1-LI in plasma from CRF consisted of small and large molecular forms of ET-1-LI. The small molecular form is presumably ET-1, and large molecular forms are big ET-1 and another component with the molecular weight of 6,000 as is the case of that in normal plasma (1). However, the ratio of the smaller to large molecular forms of ET-1-LI in CRF was 1:13 and was quite different from that in normal plasma (1:4). These observations clearly indicate that the elevation of plasma ET-1-LI level in CRF was mainly due to the increase in the large molecular form of ET-1-LI.

UR - http://www.scopus.com/inward/record.url?scp=0026343724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026343724&partnerID=8YFLogxK

M3 - Article

C2 - 1725404

AN - SCOPUS:0026343724

VL - 17

SP - S437-S439

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

ER -